S. 1097 · 119th Congress · Commerce

Interagency Patent Coordination and Improvement Act of 2025

Coordinates patent policy and procedures across federal agencies. AI-read

Out of committee1.4k words Introduced Mar 24, 2025 · Latest action Apr 10, 2025

How far it has goneStage 3 of 6
  1. IntroducedMar 24, 2025 Done
  2. CommitteeReported Apr 10, 2025 Done
  3. Senate floorAwaiting vote Current stage
  4. House floorNot yet Not reached yet
  5. Chambers agreeNot yet Not reached yet
  6. PresidentNot yet Not reached yet

What it does

This bill establishes the Interagency Task Force on Patents to support coordination and communication between the U.S. Patent and Trademark Office (USPTO) and the Food and Drug Administration (FDA) on activities relating to patents for human drugs and biological products.

The task force's duties shall include sharing information about (1) the processes of each agency, including how each agency evaluates applications (e.g., patent applications at the USPTO and new drug applications at the FDA); and (2) new approvals of patents, human drugs, biological products, and new technologies. The task force must also establish a process that requires (1) the USPTO to request from the FDA information relating to certain patent applications to help patent examiners carry out their duties, (2) the FDA to provide such information to the USPTO, and (3) the USPTO to assist the FDA in its ministerial role of listing patents.

Congressional Research Service · summary of “Introduced in Senate” version · Mar 24, 2025

Who lobbies on it

9 organizations · 55 filings · Q1 2025–Q3 2026

One square per quarter since introduction, oldest left. Filled = named it that quarter.

  1. Pharmaceutical Research and Manufacturers of America 7 of 7 quarters
    “Patent rights. Merchant rights. S.1097 - Interagency Patent Coordination and Improvement Act of 2025.”

    Q3 2026 filing · $26.6M lobbying spend in 2026 to date, all issues

  2. Novartis 7 of 7 quarters
    “S. 43: Skinny Labels, Big Savings Act S. 1096: Preserve Access to Affordable Generics and Biosimilars Act S. 1097: Interagency Patent Coordination and Improvement Act of 2025 S. 2276/HR. 3269: Eliminating Thickets to Increase Competition Act (ETHIC Act) Biopharmaceutical innovation policy issues Bayh-Dole march-in…”

    Q3 2026 filing · $6.2M lobbying spend in 2026 to date, all issues

  3. American Intellectual Property Law Association (aipla) 7 of 7 quarters
    “H.R. 10575/S. 5529, the Deterring Extraterritorial Foreign Exploitation of Networks Damaging Intellectual Property (DEFEND IP) Act of 2026 S. 5104/H.R. 9681, Fair Seeds for Farmers Act H.R. 10204, Legislative Branch Agencies Clarification Act H.R 10364 American Copyright Protection Act of 2026 H.R. 10026, Honoring…”

    Q3 2026 filing · $30K lobbying spend in 2026 to date, all issues

6 more organizations, every filingPROUpgrade

Organizations that named S. 1097 in a quarterly lobbying report. Covers organizations with a PAC on file; reports from organizations without one aren’t loaded yet. Spend is the organization’s total across all issues: reports don’t split spending by bill. Source: Senate lobbying disclosures (LD-2) from lda.gov; quotes are word for word from the “specific lobbying issues” field.

Actions

5 actions · newest first
  1. Apr 10, 2025Placed on Senate Legislative Calendar under General Orders. Calendar No. 41.
  2. Apr 10, 2025Committee on the Judiciary. Reported by Senator Grassley with amendments. Without written report.
  3. Apr 3, 2025Committee on the Judiciary. Ordered to be reported with amendments favorably.
  4. Mar 24, 2025Read twice and referred to the Committee on the Judiciary. (text: CR S1804-1805)
Show all 5 actionsShow fewer
  1. Mar 24, 2025Introduced in Senate

What members said about it

  • Statement · Press release · Apr 3, 2025 · Durbin D-IL

    Senate Judiciary Committee Advances Six Bipartisan Bills To Lower Prescription Drug Prices

    This morning, the U.S. Senate Judiciary Committee advanced six bipartisan bills to help lower the price of prescription drugs.

    “Families are struggling to afford their medications. Congress must take an all-options approach to lowering prescription drug prices, and the bills we advanced today embody that spirit. The legislative package will improve coordination between agencies, bring generic drugs to market more quickly, and foster competition…”